CAS 137862-87-4
:Valsartan
Description:
Valsartan is an angiotensin II receptor blocker (ARB) primarily used in the treatment of hypertension and heart failure. Its chemical formula is C24H29N5O3, and it features a biphenyl structure with a tetrazole ring, which contributes to its pharmacological activity. Valsartan works by inhibiting the action of angiotensin II, a hormone that causes blood vessels to constrict, thereby promoting vasodilation and reducing blood pressure. The substance is typically administered orally and is known for its relatively long half-life, allowing for once-daily dosing. Valsartan is generally well-tolerated, but like all medications, it may have side effects, including dizziness, fatigue, and potential renal impairment. It is contraindicated in certain populations, such as pregnant women, due to the risk of fetal harm. The compound is also subject to various regulatory standards to ensure its safety and efficacy in clinical use.
Formula:C24H29N5O3
InChI:InChI=1/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m1/s1
SMILES:CCCCC(=O)N(Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)[C@H](C(C)C)C(=O)O
Synonyms:- 3-Methyl-2-[Pentanoyl-[[4-[2-(2H-Tetrazol-5-Yl)Phenyl]Phenyl]Methyl]Amino]-Butanoic Acid
- N-pentanoyl-N-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}valine
- N-pentanoyl-N-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
- N-pentanoyl-N-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-D-valine
- D-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- Valsartan(Diovan)
- N-(1-Oxopentyl)-N-((2'-(1H-Tetrazol-5-Yl)(1,1'-Biphenyl)-3-Yl)Methyl)-L-Valine
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 8 products.
Valsartan Related Compound A (N-Valeryl-N-{[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}D-valine)
CAS:Aromatic or modified aromatic heterocyclic compounds withnitrogen hetero-atom(s) only nesoiFormula:C24H29N5O3Color and Shape:Off-White PowderMolecular weight:435.22704D-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
CAS:Formula:C24H29N5O3Purity:95%Color and Shape:SolidMolecular weight:435.5188Valsartan EP Impurity A (Valsartan USP Related Compound A, ent-Valsartan)
CAS:Formula:C24H29N5O3Color and Shape:White To Off-White SolidMolecular weight:435.53ent-Valsartan
CAS:<p>Impurity Valsartan USP Related Compound A<br>Applications ent-Valsartan (Valsartan USP Related Compound A) is the (R)-enantiomer of Valsartan (V095750).<br>References Corea, L., et al.: Clin. Pharmacol. Ther., 60, 341 (1996), Satana, E;., et al.: J. Pharm. Biomed. Anal., 25, 1009 (2001), Sironi, L., et al.: Hypertension, 37, 961 (2001),<br></p>Formula:C24H29N5O3Color and Shape:WhiteMolecular weight:435.52(R)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
CAS:Purity:95.0%Molecular weight:435.52801513671875N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-D-valine
CAS:<p>N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-D-valine is a potent and selective inhibitor of the enzyme lipase. It prevents the hydrolysis of triglycerides by competitively binding to the active site of lipase. This inhibition leads to an increase in serum levels of triglycerides, which are associated with cardiometabolic risk factors. Novartis developed this drug as an alternative to sacubitril/valsartan, which is used for the treatment of heart failure. The pharmacokinetics and pharmacodynamics of this drug are similar to those of sacubitril/valsartan. N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-D-</p>Formula:C24H29N5O3Purity:Min. 95%Color and Shape:White To Off-White SolidMolecular weight:435.52 g/mol








